跳至主要内容
临床试验/NL-OMON45147
NL-OMON45147招募中2 期

Prospective donor-specific Cellular alloresponse assessment for Immunosuppression Minimization in de novo renal transplantation - CELLIMI

Charite Universiteitskliniek Berlijn0 个研究点目标入组 200 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 64(—)

入选标准

  • 1) Men and women, age >=18 years.
  • 2) Subject must be a recipient of a first renal transplant from a deceased or living donor.
  • 3) Subject must have a current documented PRA <20% and no detectable anti-class I and II HLA antibodies by solid phase assay (Luminex®).
  • 4) Subject is willing to provide signed written informed consent.

排除标准

  • 1) Subjects undergoing renal transplant with a current documented PRA >20% and/or detectable anti-class I and II HLA antibodies by solid phase assay (Luminex®).
  • 2) CDC positive cross match.
  • 3) Subjects receiving an allograft from a donor older than 65 years with elevated creatinine levels and/or treated diabetes.
  • 4) Cold ischemia time (CIT) higher than 24h.
  • 5) Subjects with a prior solid organ transplant (SOT), including renal re-transplantation, or receiving a concurrent SOT.

研究者

发起方
Charite Universiteitskliniek Berlijn

相似试验